Chiron Corporation CHIR

Novartis' NVS higher bid for Chiron CHIR is obviously better for the latter firm's current shareholders than the previous offer. After vocal shareholder opposition to …

… million doses of FluMist in the 2005-06 influenza season, below previous company guidance of 2.5 to 3 million doses. Chiron CHIR , whose manufacturing facilities were shut down in 2004 due to contamination and poor process controls, was able to successfully …

… we are encouraged by the prospect of the earnings and cash flow generation that a fully consolidated Chiron Pharmaceutical CHIR will provide starting in 2006. Novartis owns 44% of Chiron but has made an offer to purchase all of the stock it doesn't …

Chiron's CHIR 2005 results showed great improvement over those of 2004, when the company encountered material setbacks stemming from its influenza …

… V. antibiotic launch in U.S. history in the 26 months since it was introduced. The company also announced that Chiron CHIR has gotten approval to market Cubicin in Britain and the Netherlands. Taking Cubist's continued sales trajectory into account …

After a failed first bid, Novartis NVS has upped the ante for Chiron CHIR shares, and the biotech firm accepted the offer this time. Chiron accepted the $45 per share offer in late October, agreeing …

Novartis NVS announced Monday that it will acquire the 58% of Chiron CHIR that it doesn't already own for about $45 per share in cash. We like the deal, but we're maintaining our fair value estimate …